Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Stock Information for Cellectar Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cellectar Biosciences Inc.

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
Cellectar Announces Plan to Explore Strategic Alternatives
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Cellectar Biosciences to Present at the 37th Annual Roth Conference
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.